 | |
| Combination of | |
|---|---|
| Abacavir | Nucleotide analoguereverse transcriptase inhibitor |
| Lamivudine | Nucleotide analoguereverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Kivexa, Epzicom, others |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a696011 |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChemCID | |
| UNII | |
| KEGG | |
| NIAID ChemDB | |
| CompTox Dashboard(EPA) | |
 N Y (what is this?) (verify) | |
Abacavir/lamivudine, sold under the brand nameKivexa among others, is afixed-dose combinationantiretroviral medication used to treatHIV/AIDS.[3] It containsabacavir andlamivudine.[3] It is generally recommended for use with otherantiretrovirals.[3] It is commonly used as part of the preferred treatment in children.[4] It is taken by mouth as a tablet.[3]
Common side effects includetrouble sleeping,headache,depression,feeling tired,nausea,rash, and fever.[3] Serious side effects may includehigh blood lactate levels,allergic reactions, andenlargement of the liver.[3] It is not recommended in people with a specificgene known asHLA-B*5701.[3] Safety inpregnancy has not been well studied but it appears to be okay.[5] Lamivudine and abacavir are bothnucleoside reverse transcriptase inhibitors (NRTI).[3]
Abacavir/lamivudine was approved for medical use in the United States in 2004.[3] It is on theWorld Health Organization's List of Essential Medicines.[6]
It is marketed as Kivexa in most countries except for the United States, where it is branded as Epzicom.[7]
Teva Pharmaceuticals andLupin Ltd both filedabbreviated new drug applications (ANDAs) relating to the treatments of HIV using various combinations of abacavir, lamivudine and AZT, and challenging various patents. In 2013 the US District Court for the District of Delaware upheld the validity of a patent covering Epzicom and Tizivir. Other matters were subject to appeal or litigation as of 20 November 2014.[8]
